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Klebsiella pneumoniae carbapenemase (KPC) 3–pro-
ducing Escherichia coli was isolated from a carrier of KPC-
3–producing  K. pneumoniae. The KPC-3 plasmid was 
identical in isolates of both species. The patient’s gut ﬂ  ora 
contained a carbapenem-susceptible E. coli strain isogenic 
with the KPC-3–producing isolate, which suggests horizon-
tal interspecies plasmid transfer. 
O
ver the past 2 years, the extremely drug-resistant 
Klebsiella pneumoniae carbapenemase (KPC)–pro-
ducing  K. pneumoniae sequence type 258 (KpnST258) 
has emerged as an important nosocomial pathogen world-
wide. It has spread in the United States and in various 
countries in Europe and Asia (1–3). The high level of an-
timicrobial drug resistance in this bacterium is conferred 
by a plasmid-encoded KPC, which confers resistance to 
all cephalosporins, monobactams, and carbapenems (4). 
Infection with carbapenem-resistant K. pneumoniae is as-
sociated with an increased proportion of deaths compared 
to carbapenem-susceptible K. pneumoniae (5). Although 
Klebsiella with plasmid-mediated carbapenem resistance is 
a major risk to hospitalized patients, spread of these resis-
tance plasmids into Escherichia coli poses an even greater 
public health threat because resistant E. coli may become 
part of the normal gut ﬂ  ora and thereby become a notable 
source of infections among sick and the healthy persons in 
healthcare settings and in the community (6).
In 2008, a carbapenem-nonsusceptible E. coli–pro-
ducing KPC-3 isolate (Eco2) was identiﬁ  ed in Tel Aviv 
Sourasky Medical Center in Israel. Until this case, carbap-
enem resistance in E. coli at the hospital was related exclu-
sively to KPC-2 production (7). KPC production in E. coli 
remains rare worldwide, even in  areas where KPC-pro-
ducing K. pneumoniae isolates are  identiﬁ  ed. We aimed 
to investigate the origin of KPC-3 in this E. coli isolate 
and to explore a possible molecular and epidemiologic link 
between the presence of blaKPC-3 in this species and in the 
KpnST258 strain prevalent in our hospital.
The Study
In April 2008 a carbapenem-nonsusceptible E. coli 
strain, marked as Eco2, was recovered from the gall blad-
der drainage of a 91-year-old man with dialysis-dependent 
end-stage renal disease, congestive heart failure, anemia, 
and peptic ulcer disease. A month earlier, the patient had 
been hospitalized with sepsis that developed after an in-
fected heel wound had required amputation of the left leg 
below the knee. The patient was treated with ertapenem, 
metronidazole, colistin, and vancomycin. Acute chole-
cystitis developed, and the patient underwent cholecys-
tostomy. During his hospital stay, the patient underwent 
screening for carriage of carbapenem-resistant Enter-
obacteriacae (CRE) as part of a routine infection control 
program aimed at limiting the spread of CRE. Two rectal 
swabs were collected 1 week apart. The ﬁ  rst swab speci-
men was negative for CRE by culture, and the second swab 
specimen showed a carbapenem-resistant K. pneumoniae 
strain (marked Kpn1), which was PCR positive for blaKPC. 
One month after the patient’s admission, a carbapenem-
nonsusceptible E. coli (Eco2) was isolated from drainage 
at the cholecystectomy site, which prompted this study.
Microbiologic and molecular investigations (pulsed-
ﬁ  eld gel electrophoresis [PFGE], DNA isolation, isoelec-
tric focusing analysis [IEF], PCR detection of resistance 
genes, plasmid isolation, transformation, and Southern 
analysis) were performed as described (2,4,7). The car-
bapenem-nonsusceptible E. coli isolated from the clinical 
specimen (Eco2) was initially identiﬁ  ed by Vitek-2 (bio-
Mérieux, Marcy-l’Etoile, France) as resistant to imipenem 
(MIC>16 mg/L). Further antimicrobial-drug susceptibility 
testing of the strain by using agar dilution and Etest (AB 
Biodisk, Solna, Sweden) showed MICs in the resistant 
range for ceftriaxone and aztreonam; in the intermediate 
range for ceftazidime and piperacillin/tazobactam; and 
in the susceptible range for cefepime, ertapenem, mero-
penem, imipenem, aminoglycosides, quinolones, tige-
cycline, and colistin (online Appendix Table, www.cdc.
gov/EID/content/16/6/1014-appT.htm). IEF identiﬁ  ed  2 
β-lactamases with isoelectric pH values of 5.4 and 6.7, cor-
responding to those of TEM-type and KPC. β-lactamase 
gene PCR screening and sequencing indicated the 
presence of blaTEM-1 and blaKPC-3. Results of screening for 
other β-lactamase genes were negative.
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Transformation of plasmids puriﬁ  ed from Eco2 into an 
E. coli DH10B recipient strain (Eco2-T) indicated transfer 
of a single plasmid that encoded these blaTEM-1 and blaKPC-3 
(Figure 1, panel A), and increased the MICs of the recipi-
ent strains to broad-spectrum cephalosporins and carbap-
enems (online Appendix Table). PFGE identiﬁ  ed the ge-
netic similarity between the colonizing Klebsiella (Kpn1) 
and a representative KpnST258 (isolate Kpn557 described 
previously [4]) (Figure 2). Susceptibility testing of Kpn1 
reﬂ  ected the extremely drug-resistant phenotype character-
istic of isolates belonging to this clone (12) (online Ap-
pendix Table).
We compared plasmids of Kpn1 and Eco2. Kpn1 car-
ried 4 different plasmids, whereas Eco2 carried 1  plasmid 
that correlated with the 105-kb plasmid of Kpn1. Experi-
ments to transform Eco2 and Kpn1 plasmids into an E. coli 
DH10B recipient, followed by selection on plates containing 
100 μg/mL ampicillin and screening for blaKPC-positive col-
onies, showed that DH10B was transformed with the105-kb 
KPC-3–encoding plasmid (Figure 1, panel A). This plasmid 
correlated in size with that of pKpQIL, the KPC-3-encoding 
plasmid of Klebsiella ST258 in Israel (13). Plasmid DNA 
restriction fragment length polymorphism showed that band 
patterns of the 2 KPC-3–encoding plasmids of Kpn1 and 
Eco2 were highly similar (98% similarity) (Figure 1, panel 
B), and Southern analysis with a blaKPC-3 probe showed the 
same hybridization pattern (Figure 1, panel C).
We aimed to determine whether the patient’s gut was 
colonized with a carbapenem-susceptible E. coli strain, 
which would ultimately serve as the in vivo recipient of 
the blaKPC-3-encoding plasmid. Thus, the ﬁ  rst broth culture 
prepared (obtained before the patient was colonized with 
KPC-3–producing  E. coli) was processed. Aliquots (0.1 
mL) were directly plated onto a MacConkey agar plate (Hy-
Labs, Rehovot, Israel). E. coli colonies isolated from the 
plate were restreaked onto a MacConkey agar plate, yield-
ing an E. coli strain 7364 (Eco1) that was susceptible to all 
antimicrobial drugs tested (online Appendix Table). PFGE 
DNA ﬁ  ngerprinting showed that Eco1 was 100% identi-
cal to the KPC-3-producing clinical strain Eco2, isolated 
from the clinical specimen (Figure 2). Plasmid analysis of 
this strain, however, proved that it lacked plasmid pKpQIL 
(results not shown).
Elements belonging to KPC transposon Tn4401, in-
cluding tnpA, tnpR, ISKpn6, and ISKpn7 (14), were iden-
tiﬁ  ed by PCR and sequencing on both KPC-3–encoding 
plasmids originating from Kpn1 and Eco2. These genetic 
determinants were absent in the susceptible Eco1. These 
data suggest that Eco1 has acquired pKpQIL from Kpn1 
in the patient’s gut, leading to the formation of Eco2. Al-
though acquisition of the plasmid increased MICs for imi-
penem, meropenem, and ertapenem considerably, it did not 
confer full resistance (online Appendix Table) presumably 
due to copy number of the plasmid or the expression level 
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Figure 1. A) Analysis of Klebsiella pneumoniae carbapenemase (KPC)–encoding plasmids in isolates Kpn1 (1), Eco2 (3), Kpn1-T (2), 
and Eco2-T (4), Israel, 2008. Plasmid size estimation was performed by digestion of DNA with S1 nuclease (20 U; Promega, Madison, 
WI, USA) followed by pulsed-ﬁ  eld gel electrophoresis (PFGE) with the CHEF-DR III apparatus (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA), as  described (8–11). Lambda ladder PFG marker (New England Biolabs, Beverly, MA, USA) was used as a molecular size marker 
(lane M). B) Restriction fragment length polymorphism of the KPC-3–encoding plasmid  from Kpn1-T (K) and Eco2-T (E). Plasmid DNA 
was digested with BamHI, BglII, EcoRI, and SacI endonucleases (New England Biolabs) and underwent PFGE on a 1% agarose gel. The 
level of similarity between restriction patterns was calculated by using GelcomparII software version 5 (Applied Maths, Kortrigk, Belgium). 
Lane M, 1-kb DNA ladder (New England Biolab). C) Southern blot analysis of plasmid DNA hybridized with blaKPC-3-labeled probe. Plasmid 
restriction products were transferred to a Hybond N+ membrane (Amersham Biosciences, Little Chalfont, United Kingdom), cross-linked 
with UV light, and hybridized with a blaKPC-3-labeled probe (892-bp product of blaKPC-3). of blaKPC-3 in E. coli. Curing of pKpQIL from Eco2 was per-
formed by sequential transfers at an  elevated temperature 
(42°C). The cured strain, which lacked the KPC-encoding 
plasmid, showed full susceptibility to all antimicrobial 
drugs tested, similar to the Eco1 strain isolated from the 
patient’s gut ﬂ  ora.
The patient received a combination of 4 antimicrobial 
agents concomitantly (ertapenem, metronidazole, colistin, 
and vancomycin) during the period in which Eco1 acquired 
in vivo the plasmid pKpQIL, thereby becoming Eco2. We 
believe that the selection pressure imposed by these anti-
microbial agents contributed to the sequence of events that 
led to plasmid transfer. We hypothesize that interspecies 
conjugation and antimicrobial pressure led to the preferen-
tial selection of Eco2, rather than Eco1, as a determinant of 
infection in this patient. 
Interspecies KPC transfer can presumably occur 
through the dissemination of mobile genetic elements as 
has been described for transfer of the mecA gene between 
strains of Staphylococcus aureus (15). blaKPC may spread 
through transfer by virtue of its location on the Tn4401 
transposon (14), or by dissemination of the intact KPC-
encoding plasmid, likely through natural conjugation. Mul-
tiple attempts to mimic the natural transfer of pKpQIL, the 
KPC-3-encoding plasmid from Kpn1 into Eco1 by using 
conjugation experiments were not successful. The isolation 
of an isogenic, antimicrobial drug–susceptible E. coli clone 
enabled us to decipher the natural order of the interspecies 
genetic transfer event 
Conclusions
With increasing global spread of KPC-producing K. 
pneumoniae ST258, the likelihood increases of interspecies 
transfer of drug-resistance determinants into a highly ﬁ  t E. 
coli clone. Such an event may have severe public health 
consequences, leading to elimination of any effective anti-
microbial drug treatment against the most common human 
bacterial pathogens.
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